news
FUJIFILM Diosynth Biotechnologies to manufacture Novavax COVID-19 vaccine candidate
Novavax and FUJIFILM Diosynth Biotechnologies have agreed for FDB to make the bulk drug substance for NVX-CoV2373, the Novavax COVID-19 vaccine candidate.
List view / Grid view
Fujifilm Diosynth Biotechnologies
Filter the results
article
Application Notes & Whitepapers 2017
This supplement contains a collection of application notes and whitepapers from some of the leading suppliers to the pharmaceutical industry...
product
FUJIFILM Diosynth Biotechnologies testing services
Technical leadership in contract development and manufacturing...
article
Guide to Outsourcing
Welcome to European Pharmaceutical Review’s Guide to Outsourcing, the fourth in our series of ‘Guide to…’ supplements. In this edition, five leading companies that provide outsourcing services explain how their portfolio meets current industry needs.
article
Biopharmaceutical Development & Processing In-Depth Focus 2017
In this in-depth focus: Non-contact single cell adhesion and micromechanical property characterisation with ultrasound. Is high resolution mass spectrometry the missing piece in continuous bioproduction? Regulatory, clinical and logistics challenges of ATMPs in clinical research...
article
World-class CDMO: process development and GMP production baculovirus expertise
Scale-up and manufacturing strategy for insect cell culture (ICC) should be assessed at the earliest stages of process development. Your final goals will shape the process and determine at what stage to implement steps that can make the process more reliable and robust at manufacturing scale. Sharyn Farnsworth, Associate Principal…